By Professor David Thomas

Book Chapters

Lin FP; Tran M; Thavaneswaran S; Grady JP; Kansara M; Chan J; Ballinger ML; Simes J; Thomas DM, 2025, 'Automating Precision Oncology Literature Curation: A Decision Tree Approach Using Large Language Models', in , pp. 248 - 252, http://dx.doi.org/10.3233/SHTI250839

Neuhaus SJ; Thomas DM, 2017, 'Multidisciplinary approach to treatment: An Australian perspective', in Sarcoma: A Multidisciplinary Approach to Treatment, Springer, pp. 461 - 476, http://dx.doi.org/10.1007/978-3-319-43121-5_23

Thomas DM; Whelan J, 2017, 'Bone Sarcomas in the Adolescent and Young Adult Population', in Bleyer A; Barr R; Ries L; Whelan J; Ferrari A (ed.), Cancer in Adolescents and Young Adults., Springer, pp. 417 - 427, http://dx.doi.org/10.1007/978-3-319-33679-4_16

Orme LM; Palmer S; Thomas D, 2009, 'No-man’s land: Between paediatric and adult medical oncology', in When Cancer Crosses Disciplines A Physician S Handbook, pp. 885 - 906, http://dx.doi.org/10.1142/9781848163652_0035

Journal articles

Jaratlerdsiri W; Soh PXY; Gong T; Jiang J; Simayi Z; Petersen DC; Holland E; Chan EKF; Theron KE; Haacke WHG; Förtsch HEA; Bornman MSR; Thomas DM; Mphahlele J; Hayes VM, 2026, 'A catalogue of early diverged contemporary human genome variation reveals distinct Khoe-San populations', Nature Communications, 17, http://dx.doi.org/10.1038/s41467-026-69269-4

Dwarte TM; Alli R; Srinivasa S; Noon F; Perera Kimmantudawage S; Gordon L; Beshay V; Joshua AM; Ruiz Araujo R; Jalilian C; Thomas DM; Smith MJ; Winship I; Ballinger ML; Li M; Tucker KM; Courtney EK, 2026, 'Challenging interpretation of low-level PTCH1 mosaicism in patients with clinically diagnosed Gorlin syndrome: a case series and review of the literature', Hereditary Cancer in Clinical Practice, 24, http://dx.doi.org/10.1186/s13053-026-00332-3

Aggerholm-Pedersen N; Handrup MM; Thomassen SB; Engelmann B; Kongstad KM; Jakobsen MV; Baad-Hansen T; Farholt S; Thomas D; Ejerskov C, 2026, 'Prevalence, treatment and survival of malignant peripheral nerve sheath tumor in the Danish neurofibromatosis type 1 population', Oncologist, 31, http://dx.doi.org/10.1093/oncolo/oyag255

Kong BY; Lin FP-Y; Espinoza D; Aberoumand M; Thavaneswaran S; Meniawy T; Desai J; Harrup R; Nayagam SS; Charakidis M; Cuff K; Sebastian L; Lee CK; Wheeler P; Kansara M; Grady JP; Thomas DM; Ballinger ML; Simes J; Goldstein D, 2026, 'Tucatinib and trastuzumab in advanced cancers with HER2 mutations or amplifications: a molecular screening and therapeutics (MoST) program substudy', npj Precision Oncology, http://dx.doi.org/10.1038/s41698-026-01590-z

McNamee N; Aref A; Poulos R; Craft G; Koh J; Xavier D; Singh A; Kansara M; Robinson P; Hains P; Ballinger M; Liu JJ; Thomas D; Reddel R, 2026, 'Abstract B051: Targeted proteomics for parallel ADC biomarker screening: a pilot feasibility study within an Australian precision oncology program', Clinical Cancer Research, 32, pp. B051 - B051, http://dx.doi.org/10.1158/1557-3265.d32026-b051

Zaheed M; Signal B; Hooshmand K; Walwyn K; Tucker K; Ballinger ML; Thomas DM, 2026, 'Clinically actionable cancer and non-cancer risk genes identified by whole genome sequencing (WGS) in early-onset tumours (EOT).', Journal of Clinical Oncology, 44, pp. 170 - 170, http://dx.doi.org/10.1200/jco.2026.44.19_suppl.170

Woodford R; Lord S; Lin F; Papenfuss AT; Marschner I; Thomas D; Friedlander M; Scott C; Simes J; Lee CK, 2026, 'Enhancing Outcome Measurement in Oncology Clinical Trials Through Artificial Intelligence: A Scoping Review', JCO Clinical Cancer Informatics, 10, pp. e2600014, http://dx.doi.org/10.1200/CCI-26-00014

Kok PS; Chan B; Aberoumoud M; Zhang A; O’Byrne K; Thavaneswaran S; Lin F; Kansara M; Corpuz T; Wheeler P; Simes RJ; Thomas D; Lee CK, 2026, 'Phase II Trial of First-Line Durvalumab and Chemotherapy in Patients With Extra-Pulmonary Small Cell Carcinoma', Jto Clinical and Research Reports, 7, http://dx.doi.org/10.1016/j.jtocrr.2026.101014

Barjesteh van Waalwijk van Doorn-Khosrovani S; Olivier T; Thomas D, 2026, 'Bypassing the evidence pathway: World-first tumour-agnostic reimbursement for dual immunotherapy', European Journal of Cancer, 241, http://dx.doi.org/10.1016/j.ejca.2026.116785

Cote GM; Aberoumand M; Choy E; Sebastian L; Mazzola E; Grimison P; Merriam P; Ballinger M; Thavaneswaran S; Lin F; Grady JP; Millward M; Brown MP; Harrup R; Espinoza D; Demetri G; Littlefield BA; Simes RJ; George S; Thomas D, 2026, 'A Phase 2 Study of Eribulin in Patients with Metastatic Angiosarcoma and Epithelioid Hemangioendothelioma', Clinical Cancer Research, 32, pp. 2206 - 2213, http://dx.doi.org/10.1158/1078-0432.CCR-25-3362

Rafati M; Guenther LM; Egolf LE; Gianferante M; Kim J; Wang K; Zhu B; Spector LG; Anderson N; Janeway KA; Barkauskas DA; Hawkins DS; Patiño-Garcia A; Lupo PJ; Scheurer ME; Morton L; Armstrong GT; Sapkota Y; Gramatges MM; Serra M; Hattinger C; Scotlandi K; Andrulis IL; Wunder JS; Ballinger ML; Thomas DM; Yeager M; Dean M; Stewart DR; Vogt A; Liu J; Hicks BD; Huang WY; Landi MT; Lori A; Diver WR; Savage SA; Chanock SJ; Mirabello L, 2026, 'SMARCAL1 is a new osteosarcoma predisposition gene', Journal of the National Cancer Institute, 118, pp. 1120 - 1125, http://dx.doi.org/10.1093/jnci/djaf278

Lin FP; Thavaneswaran S; Grady JP; Napier CE; Kansara M; Sebastian L; Kee D; Desai J; Zaheed M; Chinchen S; Oakes SR; Blackburn J; Scott HS; Glover A; Fox SB; Goldstein D; Leo P; Amanuel B; Mersiades A; Millward M; Brown MP; Charakidis M; Pokorny AMJ; Craft P; Espinoza D; Grimison P; Harrup R; Joshua AM; O'byrne K; Lee CK; Cowley MJ; Ballinger ML; Simes J; Thomas DM, 2026, 'Genomic Therapy Matching in Rare and Refractory Cancers', JAMA Oncology, 12, pp. 458 - 467, http://dx.doi.org/10.1001/jamaoncol.2026.0127

Nagrial A; Carlino MS; Gunjur A; Brown MP; Harris S; Underhill C; Zielinski R; Kee D; Lam W-S; Chan H; Harrup R; So J; Collins IM; Michael M; Chionh F; Uy C; Mariadason J; Torres J; Ballinger ML; Grady JP; Tavancheh E; Palmer J; Thomas DM; Wilkie K; Cebon J; Klein O, 2026, 'Nivolumab and ipilimumab combination treatment in patients with advanced intrahepatic cholangiocarcinoma and gallbladder cancer: Results from the phase II MoST-CIRCUIT trial.', Clin Cancer Res, http://dx.doi.org/10.1158/1078-0432.CCR-25-4009

Best MC; Descallar J; Simpson G; Napier CE; Bartley N; Ballinger ML; Goldstein D; Thomas DM; Tucker KM; Butow P, 2026, 'Impact of Spiritual Wellbeing in Advanced Cancer Patients Receiving Genomic Test Results', Psycho Oncology, 35, pp. e70471, http://dx.doi.org/10.1002/pon.70471

Thomas DM; Kim JE; Barlesi F; Martens UM; Krzakowski M; Dziadziuszko R; Jeong JH; Daniele G; Wilson TR; Wu F; Simmons BP; Patel S; Sbirnac M; Kaul M; Gadgeel SM, 2026, 'TAPISTRY: A Phase II Study of Atezolizumab in Patients with Tumor Mutational Burden–High Tumors', Clinical Cancer Research, 32, pp. 1078 - 1086, http://dx.doi.org/10.1158/1078-0432.CCR-25-3336

Koh B; Thavaneswaran S; Lin F; Grady J; Maddula M; Haghighi KS; Kansara M; Huang ML; Ballinger ML; Simes J; Thomas DM; Goldstein D, 2026, 'Exceptional Response to Durvalumab and Tremelimumab in Pancreatic Acinar Cell Carcinoma With Ultramutated Phenotype Associated With a DNA Polymerase-ε Mutation', JCO Precision Oncology, 10, http://dx.doi.org/10.1200/PO-25-01003

Lacaze P; Tiller J; Brotchie A; Nguyen-Dumont T; Steen J; Belluoccio D; Young M-A; Willis AM; Mitchell LA; Terrill B; Nowak KJ; Burns B; Horton AE; Nicholls SJ; Ademi Z; Green RC; Manchanda R; Thompson BA; Thomas D; Milne RL; Bruinsma F; Delatycki MB; Pang J; Watts GF; Macrae F; Poplawski N; Kirk J; Tucker K; Andrews L; Wallis M; Susman R; Pachter N; Sullivan D; Ragunathan A; James P; Zalcberg J; McNeil JJ; Southey MC; Winship I, 2026, 'Feasibility and outcomes of the DNA Screen nationwide adult genomic screening pilot', Nature Health, 1, pp. 90 - 98, http://dx.doi.org/10.1038/s44360-025-00020-x

Carlino MS; Gao B; Michael M; Marshall H; Gunjur A; Chan H; Zielinski R; So J; Harris SJ; Kee D; Collins IM; Lam WS; Lyle M; Underhill C; Brown MP; Harrup R; Wong SF; Grady J; Ballinger M; Tavancheh E; Thomas DM; Palmer J; Wilkie K; Cebon J; Klein O, 2026, 'Nivolumab and Ipilimumab in Advanced Mismatch Repair–Deficient/Microsatellite Instability–High Noncolorectal Cancers: A Nonrandomized Clinical Trial', JAMA Oncology, 12, pp. 39 - 47, http://dx.doi.org/10.1001/jamaoncol.2025.4721

Lefkovits YR; McLean LS; Middleton MR; Thomas DM, 2026, 'BRAF-targeted therapy in non-melanomatous BRAF-mutant tumours: a systematic review of broad but histology-modulated efficacy', International Journal of Clinical Oncology, http://dx.doi.org/10.1007/s10147-026-03079-y

Siu DHW; Lin FPY; Thomas DM; Thavaneswaran S; Espinoza D; Chinchen S; Ballinger ML; Simes RJ; Lee CK, 2026, 'Time-to-progression ratio as a potential study endpoint in early-phase oncology trials: pooled analysis of phase II trials from the Australian MoST program', Future Oncology, 22, pp. 1965 - 1974, http://dx.doi.org/10.1080/14796694.2026.2688570

Southi N; Sim H-W; Grady J; Ballinger M; Thomas D; Thavaneswaran S, 2026, '145P Characterising homologous recombination deficiencies in gliomas', ESMO Open, 11, pp. 106288 - 106288, http://dx.doi.org/10.1016/j.esmoop.2026.106288

Serrano C; Bauer S; Blay JY; Casali PG; Cicala CM; Dei Tos AP; Digklia A; Gelderblom H; Italiano A; Jones RL; Kasper B; Kyriazoglou A; Le Loarer F; Martín-Broto J; Napolitano A; Rutkowski P; Stacchiotti S; Tap W; Thomas D; Thway K; Valverde C; van der Graaf WTA; Wardelmann E; Bovée JVMG, 2025, 'Guidelines for Next-Generation Sequencing in Sarcoma Diagnosis and Treatment A Consensus Review', JAMA Oncology, 11, pp. 1527 - 1537, http://dx.doi.org/10.1001/jamaoncol.2025.3608

Jung MS; Poltavets V; Skhinas JN; Tax G; Kamili A; Xie J; Ghamrawi S; Graber P; Mao J; Wong-Erasmus M; Cui L; Kimpton K; Venkat P; Mayoh C; Lin A; Fleuren EDG; Fordham AM; Barger Z; Grady J; Thomas DM; Du EY; Graf NS; Cowley MJ; Gifford AJ; Fletcher JI; Lau LMS; Dolman MEM; Gooding JJ; Kavallaris M; Dolman E, 2025, 'High-throughput 3D engineered paediatric tumour models for precision medicine', Molecular Systems Biology, 21, pp. 1748 - 1777, http://dx.doi.org/10.1038/s44320-025-00152-y

Thavaneswaran S; Lin F; Espinoza D; Grady J; Kok PS; Chinchen S; Pavlakis N; Andelkovic V; Charakidis M; Craft P; Brown M; Desai J; Lau P; Kansara M; Simes J; Thomas D, 2025, 'A signal-seeking phase 2 study of tremelimumab in advanced cancers with high tumour mutational burden', Npj Precision Oncology, 9, http://dx.doi.org/10.1038/s41698-025-01156-5

Liang S; Kennedy E; Gale N; Watson P; Ramanathan M; Shinde A; McKay S; Torres-Robles A; Li Z; Chan J; Jones H; Ballinger ML; Butow P; Goldstein D; Leaney K; Middleton S; Morrow A; Thomas DM; Tucker KM; Zaheed M; Parkinson B; Lin F; Taylor N; Torres Robles A, 2025, 'Implementation of precision medicine in treating non-communicable diseases: a systematic review', Journal of Translational Medicine, 23, pp. 1174, http://dx.doi.org/10.1186/s12967-025-07201-y

Gheybi K; Soh PXY; Jiang J; Mbeki TMN; Louw M; Burns D; Mundra P; Kiriy D; Hasan MM; Jaratlerdsiri W; Lebelo MT; Campbell RA; Radzuma MB; Nenzhelele M; Obida M; Obida M; Ombuki WM; Oyaro MO; Patrick SM; Loda M; Wedge DC; Bristow RG; Brewer DS; Cooper CS; Reimand J; Cancel-Tassin G; Cussenot O; Hovens CM; Cocoran NM; Stricker PD; Schlomm T; Prins GS; Sørensen KD; Zanettini C; Yamaguchi TN; Xu Y; Uhrig S; Soh PXY; Sahli A; Robinson B; Reimand J; Rausch T; Queiroz LR; Pope B; Pellegrina D; Papenfuss AT; Molania R; Marchionni L; Lutsik P; Leeman G; Lamy P; Khani F; Jung CH; Jiang J; Jaratlersiri W; Jakobsdottir GM; Imada EL; He HH; Hayes VM; Hamid A; Gruber AJ; Gnanapragasam VJ; Girma EG; Gihawi A; Gerhauser C; Favero F; Corcoran NM; Cheng KCL; Butler A; Brors B; Brook MN; Bova GSS; Zhou K; Yienya A; Wanjiku GS; Walong EOO; Walker DI; Uthayopas K; Tapinos A; Stellmacher G; Shirinde J; Oyieko W; Nyaga ME; Menoe R; Maendo U; Kote-Jarai Z; Huang R; Holmes V; Gong T; Gamxamub J; Förtsch HEA; Jensby EF; Fanelli GN; Craddock J; Birch L; Barnhoorn IEJ; Argos M; Madueke IC; Moreira DM, 2025, 'Pathogenic variants reveal candidate genes for prostate cancer germline testing for men of African ancestry', Nature Communications, 16, http://dx.doi.org/10.1038/s41467-025-63865-6

van der Graaf WTA; Heiss NS; Hynes CL; Keller SP; Weinman A; Blay JY; Franco P; Giles RH; Lacombe D; Schlatter P; Thomas DM; van Waalwijk van Doorn-Khosrovani SB; Williamson M; Plummer R, 2025, 'Overcoming the barriers to treatment of rare cancer patients in the era of precision oncology: A call to action', Cancer Treatment Reviews, 140, http://dx.doi.org/10.1016/j.ctrv.2025.103013

Liang S; McKay S; Lin F; Zaheed M; Morrow A; Douglas B; Chan J; Monaghan H; Chan P; Kennedy E; Tyedmers E; Walker S; Leaney K; Napier CE; Middleton S; Butow P; Williams R; Parkinson B; Ballinger ML; Tucker K; Goldstein D; Thomas D; Taylor N, 2025, 'Integration of precision medicine into routine cancer care—protocol for the Precision Care Initiative: a research programme of effectiveness-implementation hybrid trials', BMJ Open, 15, http://dx.doi.org/10.1136/bmjopen-2024-090270

Cai Z; Boys EL; Noor Z; Aref AT; Xavier D; Lucas N; Williams SG; Koh JMS; Poulos RC; Wu Y; Dausmann M; Mackenzie KL; Aguilar-Mahecha A; Armengol C; Barranco MM; Basik M; Bowman ED; Clifton-Bligh R; Connolly EA; Cooper WA; Dalal B; Defazio A; Filipits M; Flynn PJ; Dinny Graham J; George J; Gill AJ; Gnant M; Habib R; Harris CC; Harvey K; Horvath LG; Jackson C; Kohonen-Corish MRJ; Lim E; Liu J; Long GV; Lord RV; Mann GJ; McCaughan GW; Morgan L; Murphy L; Nagabushan S; Nagrial A; Navinés J; Panizza BJ; Samra JS; Scolyer RA; Souglakos J; Swarbrick A; Thomas D; Balleine RL; Hains PG; Robinson PJ; Zhong Q; Reddel RR, 2025, 'Federated Deep Learning Enables Cancer Subtyping by Proteomics', Cancer Discovery, 15, pp. 1803 - 1818, http://dx.doi.org/10.1158/2159-8290.CD-24-1488

Gao B; Carlino MS; Michael M; Underhill C; Marshall H; Gunjur A; So J; Kee D; Antill Y; Lam WS; Chan H; Harrup R; Hamilton A; Grady J; Ballinger M; Tavancheh E; Yoon WH; Palmer J; Thomas D; Wilkie K; Cebon J; Klein O, 2025, 'Nivolumab and Ipilimumab Combination Treatment in Advanced Ovarian and Endometrial Clear Cell Cancers: A Nonrandomized Clinical Trial', JAMA Oncology, 11, pp. 982 - 989, http://dx.doi.org/10.1001/jamaoncol.2025.1916

Thavaneswaran S; Sim HW; Grady J; Espinoza D; Huang ML; Lin F; McGrath M; Desai J; Charakidis M; Brown M; Kansara M; Simes J; Thomas D, 2025, 'A phase II trial of larotrectinib in tumors with NTRK fusions or extremes of NTRK mRNA overexpression identified by comprehensive genomic profiling', Oncologist, 30, http://dx.doi.org/10.1093/oncolo/oyae339

Zhu Y; Lin FP-Y; So JY; Oh EW; Philipsen S; Thomas DM; Grady JP; Lawrence BJ; Wilson MK, 2025, 'Actionability of genomic alterations in the Molecular Screening and Therapeutics (MoST) program in New Zealand (NZ) depending on residence in NZ or Australia.', JOURNAL OF CLINICAL ONCOLOGY, 43, pp. E13763 - E13763, http://dx.doi.org/10.1200/JCO.2025.43.16_suppl.e13763

Spencer S; Ye W; Napier C; Lin FP-Y; Thomas DM; Chan R; Ballinger ML; Morton RL; Berber S; Zou D; Peng S, 2025, 'Clinical and economic value of comprehensive genomic profiling in patients with advanced solid cancers using Australian real-world data: Preliminary analyses.', JOURNAL OF CLINICAL ONCOLOGY, 43, pp. e15084 - e15084, http://dx.doi.org/10.1200/JCO.2025.43.16_suppl.e15084

Lin FP-Y; Goldstein D; Grady JP; Napier C; Thavaneswaran S; Pitiyarachchi O; Kansara M; Chantrill LA; Sjoquist K; Thornton K; Raina A; Magenau A; Simes J; Ballinger ML; Sharbeen G; Timpson P; Pajic M; Phillips P; Thomas DM, 2025, 'Genomic and outcome analysis of recurrent versus de novo metastatic pancreatic ductal adenocarcinoma (PDAC) receiving systemic therapy: Results from the Australian MoST and CaSP screening programs.', JOURNAL OF CLINICAL ONCOLOGY, 43, pp. 4120 - 4120, http://dx.doi.org/10.1200/JCO.2025.43.16_suppl.4120

Lin FP-Y; Huang ML; Grady JP; Thavaneswaran S; Kansara M; Napier C; Ballinger ML; Simes J; Thomas DM, 2025, 'Machine learning-based classification of cancer types using genomic profiling data from the Australian Molecular Screening and Therapeutics (MoST) program.', JOURNAL OF CLINICAL ONCOLOGY, 43, pp. e13683 - e13683, http://dx.doi.org/10.1200/JCO.2025.43.16_suppl.e13683

Kohlmann W; Curtin K; Madsen MJ; Camp NJ; Jeter JM; Ballinger ML; Thomas DM; Garber JE; Schiffman JD, 2025, 'Population-based assessment of leiomyosarcoma (LMS) and cancers in the Li-Fraumeni syndrome (LFS) spectrum: Implications for genetic testing criteria', JOURNAL OF CLINICAL ONCOLOGY, 43, http://dx.doi.org/10.1200/JCO.2025.43.16_suppl.11570

Connolly EA; Boye K; Bonvalot S; Kratz CP; Leithner A; Malkin D; Messiou C; Miah AB; Pantziarka P; Timmermann B; van der Graaf WTA; Thomas DM; Stacchiotti S, 2025, 'Genetic predisposition in sarcomas: clinical implications and management', Eclinicalmedicine, 83, http://dx.doi.org/10.1016/j.eclinm.2025.103203

Gadgeel SM; Fajardo O; Barlesi F; Eun Kim J; Kurzrock R; Thomas DM; Jagtiani R; Noe J; Schwemmers S; Nikolaidis C, 2025, 'Real-world characteristics and survival outcomes of patients with metastatic ALK fusion-positive solid tumors treated with standard-of-care therapies', Oncologist, 30, http://dx.doi.org/10.1093/oncolo/oyaf005

McParland K; Koh ES; Kong B; Sim HW; Thavaneswaran S; Yip S; Barnes EH; Ballinger ML; Thomas DM; De Abreu Lourenco R; Simes J; Sebastian L; Wheeler PJ; Spyridopoulos D; Hawkins C; Pitz M; O'Callaghan C; Gan HK, 2025, 'Low & Anaplastic Grade Glioma Umbrella Study of MOlecular Guided TherapieS (LUMOS-2): study protocol for a phase 2, prospective, multicentre, open-label, multiarm, biomarker-directed, signal-seeking, umbrella, clinical trial for recurrent IDH mutant, grade 2/3 glioma', BMJ Open, 15, http://dx.doi.org/10.1136/BMJOPEN-2024-087922

Novis E; Glover A; Grady JP; Silvestri A; Thavaneswaran S; Lin F; Ballinger ML; Thomas DM, 2025, 'Oncogenic mutations in the TP53 and PI-3 kinase/AKT pathway are independent predictors of survival for advanced thyroid cancer: Analysis from the Molecular Screening and Therapeutics (MoST) program', Surgery United States, 177, http://dx.doi.org/10.1016/j.surg.2024.05.058

Ballinger ML; Thomas DM, 2025, 'POT1 clinical risk management is an open question', European Journal of Human Genetics, 33, pp. 3 - 4, http://dx.doi.org/10.1038/s41431-024-01676-x

Horgan D; Tanner M; Aggarwal C; Thomas D; Grover S; Basel-Salmon L; Dienstmann R; Tan TJY; Park WY; Abu Rasheed HM; Siu LL; Ma B; Ortiz-López R; Van Den Bulcke M; Taucher SC; Ferris A; Starling N; Malapelle U; Longshore J; Saldaña HAB; Subbiah V, 2025, 'Precision Oncology: A Global Perspective on Implementation and Policy Development', JCO Global Oncology, 11, http://dx.doi.org/10.1200/GO-24-00416

Gaughran G; Body A; Thavaneswaran S; Bellinger M; Harris SJ; Davies AG; Huang ML; Kee D; Thomas D, 2025, '82P Y220C, a rare but druggable TP53 mutation: A molecular landscape in an Australian context', ESMO Open, 10, pp. 105432 - 105432, http://dx.doi.org/10.1016/j.esmoop.2025.105432

Kansara M; Thavaneswaran S; Lin FP; Kok P-S; Grady J; Thomas H; Corpuz T; Mundra P; Lu J; Ballinger M; Desai J; Harrup RA; Craft P; Charakidis M; O'Byrne KJ; Selva-Nayagam S; Millwar M; Grimiso P; Simes J; Thomas D, 2025, 'A phase II trial of palbociclib and avelumab in advanced solid tumours with CDK4/6 pathway alterations', ANNALS OF ONCOLOGY, 36, http://dx.doi.org/10.1016/j.annonc.2025.08.2175

Srinivasa S; Fletcher C; Zhang BY; Goodwin A; Palme CE; Bhadri VA; Grimison PS; Thomas DM; Maclean F; Gupta R; Connolly EA, 2025, 'EP300::VGLL3 rhabdomyosarcoma: a potential distinct indolent adult rhabdomyosarcoma subtype', ESMO Rare Cancers, 2, pp. 100012 - 100012, http://dx.doi.org/10.1016/j.esmorc.2025.100012

Gaughran G; Zaheed M; Harris SJ; Napier C; Yap M; Bellinger M; Grady J; Kee D; Caillet V; Davies A; Thavaneswaran S; Thomas DM, 2025, 'HIF2α pathway aberrations across tumour types: A rare but actionable entity with high germline conversion', ANNALS OF ONCOLOGY, 36, http://dx.doi.org/10.1016/j.annonc.2025.10.1192

Back to profile page